Acquired in-process research and development asset.

No definition available.

Name:	fgen_AcquiredInProcessResearchAndDevelopmentAsset
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative arrangement aggregate consideration for milestone and upfront payments.

+ References

No definition available.

+ Details

Name:	fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Percentage of pre-launch inventory capitalized of aggregate inventory balance.

+ References

No definition available.

+ Details

Name:	fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance
Namespace Prefix:	fgen_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Supplies, net.

+ References

No definition available.

+ Details

Name:	fgen_SuppliesNet
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Transfer price true up.

+ References

No definition available.

+ Details

Name:	fgen_TransferPriceTrueUp
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

+ Details

Name:	us-gaap_Depreciation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 8A
-URI http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562

+ Details

Name:	us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_LicenseAgreementWithEluminexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_HiFiBiOAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_CN
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Balance Sheet Components - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jul. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Other-than-temporary impairment loss	$ 0
Net unbilled co-development revenue	8,000,000	$ 8,000,000	$ 0
Depreciation expense		10,170,000	11,678,000	$ 11,147,000
Profit share liability	15,857,000	15,857,000	6,547,000
Acquired in-process research and development asset	35,000,000	35,000,000	$ 0
Eluminex [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled upfront payment	8,000,000.0	8,000,000.0			$ 8,000,000.0
AstraZeneca Agreements [Member]
Schedule of Available-for-sale Securities [Line Items]
Net unbilled co-development revenue	9,100,000	9,100,000
HiFiBiO Agreement [Member]
Schedule of Available-for-sale Securities [Line Items]
Acquired in-process research and development asset	$ 35,000,000.0	$ 35,000,000.0
U.S. [Member]
Schedule of Available-for-sale Securities [Line Items]
Percentage of pre-launch inventory capitalized of aggregate inventory balance	38.00%	38.00%	29.00%
Europe [Member] \| Astellas Agreement [Member]
Schedule of Available-for-sale Securities [Line Items]
Transfer price true up	$ 49,800,000	$ 49,800,000
China [Member] \| AstraZeneca Agreements [Member]
Schedule of Available-for-sale Securities [Line Items]
Profit share liability	$ 7,900,000	$ 7,900,000	$ 7,000,000.0